metformin has been researched along with Burkitt Lymphoma in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Burkitt Lymphoma: A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vu, K | 1 |
| Busaidy, N | 1 |
| Cabanillas, ME | 1 |
| Konopleva, M | 1 |
| Faderl, S | 1 |
| Thomas, DA | 1 |
| O'Brien, S | 1 |
| Broglio, K | 1 |
| Ensor, J | 1 |
| Escalante, C | 1 |
| Andreeff, M | 1 |
| Kantarjian, H | 1 |
| Lavis, V | 1 |
| Yeung, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia[NCT00500240] | Phase 3 | 52 participants (Actual) | Interventional | 2004-04-30 | Terminated (stopped due to Terminated early due to futility.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The overall survival rate defined as percentage of participants in each treatment group who are still alive at 12 months. (NCT00500240)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Conventional Care | 80.8 |
| Intensive Insulin | 63.5 |
Overall survival (OS) defined as the interval between the date of randomization and the date of death. Calculation of period was from baseline (date of randomization) to the death or last follow-up. (NCT00500240)
Timeframe: Baseline (date of randomization) to date of death or last follow-up (weekly during treatment then every 2 months post study treatment) up to 6 years
| Intervention | Months (Median) |
|---|---|
| Conventional Care | 44 |
| Intervention Group | 62.2 |
PFS was defined as the time interval between the date of complete remission and the date of relapse detection or death. Complete Remission (CR) defined as granulocyte count >1.0 × 10^9/L, platelet count >100 × 10^9/L, no abnormal peripheral blasts, and <5% blasts in normocellular or hypercellular bone marrow. (NCT00500240)
Timeframe: Date of complete remission to disease progression, assessed for approximately 6 years
| Intervention | Months (Median) |
|---|---|
| Conventional Care | 38.8 |
| Intensive Insulin | 24 |
1 trial available for metformin and Burkitt Lymphoma
| Article | Year |
|---|---|
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Gl | 2012 |